Medical Conference Calendar 2025

Archive · 41 conferences

Key presentations from 2025 conferences

Curated selection of 80 key Phase 2/3 readouts and late-breaking abstracts from major pharma companies (not a complete list). Pro members see drug details, indications, trial names, and next expected milestones.

Unlock Pro →

Disease area

Tier 1 only

January 2025

ASCO GI — ASCO GI Cancers Symposium 1 pres

Jan 23–25, 2025 · San Francisco, CA

Google iCal

Oncology Gastroenterology

February 2025

ASCO GU — ASCO GU Cancers Symposium 1 pres

Feb 13–15, 2025 · San Francisco, CA

Google iCal

Oncology Urology

ECCO — ECCO Congress

Feb 19–22, 2025 · Vienna, Austria

Google iCal

Gastroenterology Immunology

March 2025

AAD — AAD Annual Meeting Tier 1 2 pres

Mar 7–11, 2025 · Orlando, FL

Google iCal

Dermatology

CROI — CROI Tier 1 1 pres

Mar 9–12, 2025 · San Francisco, CA

Google iCal

Infectious Disease

ESGO — ESGO Congress

Mar 13–16, 2025 · Singapore

Google iCal

Oncology

SGO — SGO Annual Meeting Tier 1

Mar 14–17, 2025 · Denver, CO

Google iCal

Oncology

ACC — ACC Annual Scientific Session Tier 1

Mar 29–31, 2025 · Chicago, IL

Google iCal

Cardiovascular

April 2025

AD/PD — AD/PD International Conference

Apr 2–6, 2025 · Vienna, Austria

Google iCal

Neurology

AAN — AAN Annual Meeting Tier 1 2 pres

Apr 5–9, 2025 · San Diego, CA

Google iCal

Neurology

HRS — Heart Rhythm Scientific Sessions

Apr 24–27, 2025 · San Diego, CA

Google iCal

Cardiovascular

AACR — AACR Annual Meeting Tier 1 8 pres

Apr 25–30, 2025 · Chicago, IL

Google iCal

Oncology

AUA — AUA Annual Meeting

Apr 26–29, 2025 · Las Vegas, NV

Google iCal

Urology Oncology

May 2025

DDW — Digestive Disease Week Tier 1 2 pres

May 3–6, 2025 · Washington, DC

Google iCal

Gastroenterology Immunology

EASL — EASL Congress

May 7–10, 2025 · Milan, Italy

Google iCal

Gastroenterology

ATS — ATS International Conference Tier 1

May 16–21, 2025 · San Francisco, CA

Google iCal

Pulmonology

EAS — EAS Congress

May 18–21, 2025 · Oslo, Norway

Google iCal

Cardiovascular

ASCO — ASCO Annual Meeting Tier 1 16 pres

May 30 – Jun 3, 2025 · Chicago, IL

Google iCal

Oncology

June 2025

EULAR — EULAR Congress 1 pres

Jun 11–14, 2025 · Barcelona, Spain

Google iCal

Rheumatology Immunology

EHA — EHA Congress Tier 1

Jun 12–15, 2025 · Milan, Italy

Google iCal

Hematology Oncology

ADA — ADA Scientific Sessions Tier 1 5 pres

Jun 20–23, 2025 · Chicago, IL

Google iCal

Endocrinology Metabolic

ISTH — ISTH Congress

Jun 22–26, 2025 · Copenhagen, Denmark

Google iCal

Hematology Cardiovascular

August 2025

ESC — ESC Congress Tier 1 2 pres

Aug 29 – Sep 1, 2025 · London, UK

Google iCal

Cardiovascular

September 2025

WCLC — WCLC Tier 1 2 pres

Sep 7–10, 2025 · Vienna, Austria

Google iCal

Oncology

EASD — EASD Annual Meeting Tier 1

Sep 11–14, 2025 · Madrid, Spain

Google iCal

Endocrinology Metabolic

ESMO — ESMO Congress Tier 1 12 pres

Sep 12–16, 2025 · Barcelona, Spain

Google iCal

Oncology

ERS — ERS International Congress 2 pres

Sep 13–17, 2025 · Madrid, Spain

Google iCal

Pulmonology

ECTRIMS — ECTRIMS 1 pres

Sep 17–20, 2025 · Barcelona, Spain

Google iCal

Neurology

October 2025

IDWeek — IDWeek

Oct 15–18, 2025 · Los Angeles, CA

Google iCal

Infectious Disease

AAO — AAO Annual Meeting Tier 1

Oct 18–21, 2025 · Las Vegas, NV

Google iCal

Ophthalmology

CHEST — CHEST Annual Meeting

Oct 19–22, 2025 · Chicago, IL

Google iCal

Pulmonology

EADV — EADV Congress Tier 1 2 pres

Oct 22–25, 2025 · Amsterdam, Netherlands

Google iCal

Dermatology

November 2025

ObesityWeek — ObesityWeek Tier 1 2 pres

Nov 1–4, 2025 · San Antonio, TX

Google iCal

Metabolic Endocrinology

TCT — TCT Annual Conference

Nov 1–4, 2025 · Washington, DC

Google iCal

Cardiovascular

SITC — SITC Annual Meeting 2 pres

Nov 6–8, 2025 · Houston, TX

Google iCal

Oncology Immunology

ACR — ACR Convergence Tier 1 3 pres

Nov 14–19, 2025 · Washington, DC

Google iCal

Rheumatology Immunology

AASLD — The Liver Meeting (AASLD)

Nov 14–18, 2025 · San Francisco, CA

Google iCal

Gastroenterology

AHA — AHA Scientific Sessions Tier 1 3 pres

Nov 15–17, 2025 · Chicago, IL

Google iCal

Cardiovascular

CTAD — CTAD Tier 1 1 pres

Nov 17–21, 2025 · San Diego, CA

Google iCal

Neurology

SNO — SNO Annual Meeting

Nov 19–23, 2025 · Boston, MA

Google iCal

Oncology Neurology

December 2025

ASH — ASH Annual Meeting Tier 1 9 pres

Dec 6–9, 2025 · New Orleans, LA

Google iCal

Hematology Oncology

Key Presentations

Curated selection of 80 notable readouts (not comprehensive)

Unlock Pro →

ASCO GI — ASCO GI Cancers Symposium

oral

KEYTRUDA · Merck · Biliary tract cancer · KEYNOTE-966 ↗

KEYNOTE-966 sets standard; pembro in BTC label update; PD-L1 biomarker refinement

ASCO GU — ASCO GU Cancers Symposium

oral

TALZENNA · Pfizer · mCRPC + HRR mutations · TALAPRO-3 ↗

TALAPRO-3 FDA filing for nmCRPC + HRR mutations; decision expected 2026

AAD — AAD Annual Meeting

oral

DUPIXENT · Sanofi · Atopic dermatitis (pediatric) · LIBERTY AD PEDS ↗

Dupixent in CSU Phase 3 LIBERTY-CSU CUPID readout expected 2026

oral

DUPIXENT · Regeneron · Prurigo nodularis · LIBERTY-PN PRIME2 ↗

Dupixent in CSU Phase 3 LIBERTY-CSU CUPID readout expected 2026

CROI — CROI

oral

VOCABRIA · GSK · HIV-1 maintenance therapy · ATLAS-2M 3-year follow-up ↗

LA cabotegravir 6-month dosing Phase 3 data expected; HIV prevention indication watch

AAN — AAN Annual Meeting

oral

KISUNLA · Eli Lilly · Early symptomatic Alzheimer's disease · TRAILBLAZER-ALZ 2 ↗

TRAILBLAZER-ALZ 3 prevention trial ongoing; head-to-head lecanemab vs donanemab watch

poster

FARXIGA · AstraZeneca · Stroke prevention in T2D · DECLARE-TIMI 58 secondary analysis ↗

AACR — AACR Annual Meeting

oral

VENCLEXTA · AbbVie · AML frontline · VIALE-A 4-year follow-up ↗

VIALE-A OS continues to mature; venetoclax backbone in AML expanding

oral

DARZALEX FASPRO · J&J · Smoldering multiple myeloma · AQUILA ↗

FDA filing for smoldering MM prevention expected 2025–2026

oral

TALZENNA · Pfizer · mCRPC + HRR mutations · TALAPRO-2 ↗

TALAPRO-2 final OS analysis; TALAPRO-3 readout at ASCO-GU 2026

oral

RETEVMO · Eli Lilly · RET-altered thyroid & lung cancers · LIBRETTO-001 ↗

LIBRETTO-431 Phase 3 OS results expected 2026

oral

KRAZATI · Bristol-Myers Squibb · KRAS G12C-mutated NSCLC · KRYSTAL-1 ↗

KRYSTAL-12 Phase 3 vs docetaxel: OS readout expected mid-2026

oral

ENHERTU · AstraZeneca · HER2+ gastric/GEJ cancer · DESTINY-Gastric04 ↗

oral

LIBTAYO · Regeneron · Advanced cutaneous squamous cell carcinoma · EMPOWER-cSCC-1 ↗

oral

TECVAYLI · J&J · Relapsed/refractory multiple myeloma · MajesTEC-1 ↗

MajesTEC-7 Phase 3 confirmatory trial ongoing; sBLA filing watch 2026

DDW — Digestive Disease Week

oral

SKYRIZI · AbbVie · Crohn's disease · ADVANCE / MOTIVATE induction + FORTIFY maintenance ↗

SEQUENCE head-to-head vs ustekinumab OS ongoing; risankizumab UC filing expected 2026

oral

RINVOQ · AbbVie · Ulcerative colitis · U-ACHIEVE maintenance 2-year extension ↗

U-ACHIEVE long-term extension; upadacitinib positioning in biologic-naive UC

ASCO — ASCO Annual Meeting

oral

IMBRUVICA · AbbVie · CLL first-line · ECOG-ACRIN E1912 7-year follow-up ↗

LBA

RYBREVANT · J&J · EGFR-mutated NSCLC first-line · MARIPOSA ↗

oral

LORBRENA · Pfizer · ALK+ NSCLC first-line · CROWN ↗

oral

VERZENIO · Eli Lilly · Early HR+/HER2- breast cancer · monarchE ↗

monarchE OS analysis maturing; final OS readout expected 2026–2027

LBA

JAYPIRCA · Eli Lilly · Relapsed/refractory CLL/SLL · BRUIN CLL-321 ↗

FDA filing for R/R CLL expected H2 2025; approval decision watch 2026

oral

OPDIVO · Bristol-Myers Squibb · Resectable NSCLC neoadjuvant · CheckMate 816 ↗

CheckMate 816 OS data maturing; nivolumab neoadjuvant standard of care solidifying

oral

OPDUALAG · Bristol-Myers Squibb · Melanoma first-line · RELATIVITY-047 ↗

RELATIVITY-047 final OS analysis expected 2026

LBA

Tagrisso · AstraZeneca · Unresectable stage III EGFR+ NSCLC · LAURA ↗

FDA approved Sep 2025 for stage III EGFR+ NSCLC (LAURA indication)

oral

ENHERTU · AstraZeneca · HER2-low/ultralow breast cancer · DESTINY-Breast06 ↗

sNDA filed for HER2-ultralow mBC; FDA decision watch 2026

oral

LIBTAYO · Regeneron · Cervical cancer · KEYNOTE-826 / EMPOWER-Cervical ↗

Confirmatory Phase 3 ongoing; updated OS readout expected 2026

oral

TRODELVY · Gilead Sciences · HR+/HER2- metastatic breast cancer · TROPiCS-02 ↗

ASCENT-03 first-line TNBC readout at ESMO 2025; potential label expansion

oral

KEYTRUDA · Moderna · Melanoma adjuvant · V940-001 (mRNA-4157 + pembrolizumab) ↗

Phase 3 KEYNOTE-942 pivotal enrollment complete; OS readout expected 2026

oral

KEYTRUDA · Merck · TNBC neoadjuvant · KEYNOTE-522 ↗

Phase 3 KEYNOTE-942 pivotal enrollment complete; OS readout expected 2026

oral

KEYTRUDA · Merck · MSI-H/dMMR colorectal cancer first-line · KEYNOTE-177 ↗

Phase 3 KEYNOTE-942 pivotal enrollment complete; OS readout expected 2026

oral

JEMPERLI · GSK · Endometrial cancer first-line · RUBY ↗

RUBY OS establishes dostarlimab as 1L standard in dMMR endometrial; Part 2 data expected

oral

BLENREP · GSK · Relapsed/refractory multiple myeloma · DREAMM-7 ↗

DREAMM-7 sNDA for bortezomib combination; belantamab re-approval watch 2025–2026

EULAR — EULAR Congress

oral

SAPHNELO · AstraZeneca · Systemic lupus erythematosus · TULIP-2 long-term extension ↗

TULIP-2 5yr OLE real-world alignment; lupus nephritis Phase 3 IRIS ongoing

ADA — ADA Scientific Sessions

LBA

MOUNJARO · Eli Lilly · T2D cardiovascular outcomes · SURPASS-CVOT ↗

SURPASS-CVOT sNDA filing expected 2025; FDA CV indication decision 2026

oral

ZEPBOUND · Eli Lilly · Obesity with obstructive sleep apnea · SURMOUNT-OSA ↗

FDA approved for OSA (Jun 2024); SURMOUNT-CVOT cardiovascular outcomes trial ongoing

LBA

RYBELSUS · Novo Nordisk · T2D cardiovascular outcomes · SOUL ↗

SOUL sNDA for CV risk reduction filed; FDA decision watch 2026

LBA

OZEMPIC · Novo Nordisk · CKD in T2D · FLOW ↗

FDA approved for CKD in T2D (Mar 2024); long-term FLOW extension ongoing

oral

REPATHA · Amgen · CV risk reduction in T2D · VESALIUS-CV ↗

ESC — ESC Congress

LBA

WEGOVY · Novo Nordisk · Obesity + cardiovascular disease · SELECT 3-year follow-up ↗

SELECT OS analysis ongoing; heart failure hospitalisation benefit label update watch

oral

MOUNJARO · Eli Lilly · T2D cardiovascular outcomes · SURPASS-CVOT ↗

SURPASS-CVOT label filing for CV risk reduction; head-to-head vs GLP-1 data at ESC 2026

WCLC — WCLC

oral

TAGRISSO · AstraZeneca · EGFR+ NSCLC adjuvant · ADAURA 5-year OS ↗

ADAURA final OS; LAURA long-term OS follow-up presented at WCLC 2026

oral

LIBTAYO · Regeneron · Small cell lung cancer · EMPOWER-Lung 4 ↗

EMPOWER-Lung 4 OS; cemiplimab SCLC positioning vs atezo/durva

ESMO — ESMO Congress

oral

VENCLEXTA · AbbVie · CLL relapsed/refractory · MURANO 7-year follow-up ↗

MURANO final OS; venetoclax fixed-duration becoming standard in R/R CLL

oral

RYBREVANT · J&J · EGFR exon 20 insertion NSCLC · PAPILLON ↗

PAPILLON OS final analysis; amivantamab + chemo becoming 1L standard for exon 20

oral

IBRANCE · Pfizer · HR+/HER2- early breast cancer · PALLAS / PENELOPE-B combined analysis ↗

Pooled analysis to define predictive biomarkers; CDK4/6i adjuvant benefit question ongoing

oral

VERZENIO · Eli Lilly · Early HR+/HER2- breast cancer · monarchE ↗

monarchE final OS analysis; abemaciclib adjuvant duration data

oral

OPDIVO · Bristol-Myers Squibb · Gastric/GEJ cancer first-line · CheckMate 649 ↗

CheckMate 649 final OS; nivolumab + chemo now standard of care in PD-L1 CPS≥5 gastric

oral

ENHERTU · AstraZeneca · HER2+ NSCLC · DESTINY-Lung04 ↗

FDA filing for HER2-mutant NSCLC 2nd-line; decision expected 2026

LBA

KISQALI · Novartis · Early breast cancer · NATALEE ↗

NATALEE OS analysis maturing; potential early BC standard of care shift

oral

LIBTAYO · Regeneron · NSCLC first-line · EMPOWER-Lung 3 ↗

EMPOWER-Lung 3 OS final analysis; label update expected

oral

SARCLISA · Sanofi · Newly diagnosed multiple myeloma · IMROZ ↗

IMROZ OS readout expected 2026; potential frontline standard of care

oral

TRODELVY · Gilead Sciences · Triple-negative breast cancer · ASCENT-03 ↗

ASCENT-03 FDA filing for 1L TNBC expected 2026 if approved

oral

KEYTRUDA · Merck · NSCLC first-line · KEYNOTE-189 ↗

KEYNOTE-189 long-term OS; pembrolizumab backbone in non-sq NSCLC established

oral

ZEJULA · GSK · Ovarian cancer maintenance · PRIMA 5-year follow-up ↗

PRIMA 5yr OS final analysis; PARP inhibitor maintenance positioning post-ATHENA

ERS — ERS International Congress

oral

DUPIXENT · Sanofi · COPD with type 2 inflammation · NOTUS ↗

FDA approved for COPD Jun 2024; NOTUS real-world data and COPD label expansion ongoing

oral

FASENRA · AstraZeneca · Severe eosinophilic asthma · ANDHI ↗

ANDHI filing for severe asthma subtype; benralizumab SC label update watch 2026

ECTRIMS — ECTRIMS

oral

SAPHNELO · AstraZeneca · NMOSD · CHAMPION-NMOSD ↗

CHAMPION-NMOSD filing for NMOSD indication; anifrolumab expanding CNS indications

EADV — EADV Congress

oral

SKYRIZI · AbbVie · Plaque psoriasis · IMMhance 3-year extension ↗

Long-term PASI 100 durability data; risankizumab market share vs IL-17 agents

oral

RINVOQ · AbbVie · Atopic dermatitis · Measure Up 1 & 2 combined extension ↗

Upadacitinib AD indication growing; head-to-head vs dupilumab trial data watch

ObesityWeek — ObesityWeek

oral

WEGOVY · Novo Nordisk · Obesity long-term maintenance · STEP 5 extension ↗

STEP UP higher-dose (7.2mg) Phase 3 readout expected 2026

LBA

ZEPBOUND · Eli Lilly · Obesity · SURMOUNT-5 ↗

SURMOUNT-5 full data publication; head-to-head vs Wegovy competitive positioning

SITC — SITC Annual Meeting

oral

KEYTRUDA · Moderna · NSCLC · V940-001 (mRNA-4157 + pembrolizumab) ↗

Phase 3 V940-001 pivotal enrollment complete; primary OS readout expected ASCO/ESMO 2026

oral

JEMPERLI · GSK · MSI-H/dMMR solid tumors · GARNET expansion cohorts ↗

GARNET BLA supplemental for tumor-agnostic dMMR indication; FDA decision watch 2026

ACR — ACR Convergence

oral

RINVOQ · AbbVie · Psoriatic arthritis · SELECT-PsA 1 & 2 combined analysis ↗

JAK inhibitor class-wide label changes post-ORAL Surveillance; upadacitinib benefit-risk data

oral

TREMFYA · J&J · Psoriatic arthritis · DISCOVER-2 5-year follow-up ↗

Guselkumab DISCOVER-2 long-term structural damage prevention data; IL-23 vs IL-17 in PsA

oral

SAPHNELO · AstraZeneca · Systemic lupus erythematosus · TULIP-2 2-year open-label extension ↗

TULIP-2 OLE 5yr OS; anifrolumab positioning in lupus nephritis watch 2026

AHA — AHA Scientific Sessions

oral

FARXIGA · AstraZeneca · Heart failure · DELIVER follow-up ↗

DELIVER 5yr OS final analysis; dapagliflozin outcomes across full HF spectrum

poster

ZEJULA · GSK · Heart failure prevention in post-MI · GALACTIC-HF reanalysis ↗

oral

VYNDAMAX · Pfizer · ATTR cardiomyopathy · ATTR-ACT long-term extension ↗

Acoramidis (BridgeBio) approval Jan 2025 increases competition; biosimilar timeline watch

CTAD — CTAD

oral

LEQEMBI · Biogen · Early Alzheimer's disease · CLARITY AD 3-year extension ↗

Leqembi SC (subcutaneous) Phase 3 AHEAD 3-45 primary data expected 2026

ASH — ASH Annual Meeting

oral

VENCLEXTA · AbbVie · CLL first-line fixed-duration · GLOW 5-year follow-up ↗

GLOW OS final; ibrutinib + venetoclax fixed-duration vs continuous BTKi ongoing debate

oral

DARZALEX FASPRO · J&J · Newly diagnosed multiple myeloma · PERSEUS ↗

PERSEUS OS maturing; dara-VRd likely to become transplant-eligible NDMM standard

oral

TALVEY · J&J · Relapsed/refractory multiple myeloma · MonumenTAL-1 ↗

MonumenTAL-2 bispecific combination data expected ASH 2026; Phase 3 enrollment ongoing

oral

ELREXFIO · Pfizer · Relapsed/refractory multiple myeloma · MagnetisMM-3 ↗

MagnetisMM-9 Phase 3 confirmatory trial; sBLA supplemental filing watch 2026

oral

REBLOZYL · Bristol-Myers Squibb · Lower-risk MDS · COMMANDS ↗

COMMANDS label update filed; luspatercept replacing ESA as standard in lower-risk MDS

oral

ABECMA · Bristol-Myers Squibb · Relapsed/refractory multiple myeloma · KarMMa-3 ↗

KarMMa-5 earlier-line trial enrolling; ide-cel vs carvykti competitive positioning

oral

CALQUENCE · AstraZeneca · CLL first-line · ELEVATE-TN ↗

ELEVATE-TN final OS; acalabrutinib positioning vs zanubrutinib in treatment-naïve CLL

oral

CARVYKTI · J&J · Multiple myeloma earlier lines · CARTITUDE-4 ↗

CARTITUDE-4 OS final; ciltacabtagene expanding into 2nd-line MM watch 2026

oral

BLENREP · GSK · Relapsed/refractory multiple myeloma · DREAMM-8 ↗

DREAMM-8 OS final; pomalidomide combination sBLA filing expected 2026

See drug details, indications, and next milestones

Unlock with Pro →